Alongside the success of fexaramine, the direct administration of gut FXR-antagonistic BAs such as taurine/glycine conjugated βMCA and UDCA have been shown to prevent and reverse HF DIO, insulin resistance, hyperglycemia, and steatosis in mice. Here, NR1H4 is linked to steatosis.